By closing off the left atrial appendage, the risk of stroke is reduced and over time, and patients may be able to stop taking other medications.’ The Watchman device has been implanted in more ...

WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) device, enhancing stroke prevention options for patients with non-valvular ...

Boston Scientific’s BSX robust expansion of operations across different geographies outside the United States is poised to help it grow in the upcoming quarters. The company’s Electrophysiology (EP) ...

Boston Scientific is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53 BSX has reported YOY quarterly earnings growth of -6.3% and gross profit margins ...

It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that ...

Erlanger Cardiology completed the first in Chattanooga concomitant left atrial appendage closure (LAAC) and cardiac ablation for atrial fibrillation (AFib) on Nov. 23. Officials said, "This is an ...

The global large bore vascular closure device market is a dynamic and rapidly evolving segment of the medical device industry, primarily driven by the increasing prevalence of cardiovascular diseases, ...

Moving into 2025, Shivkumar said the field will be seeing more data on the use of implantable and wearable devices. In addition, he said, “we will be looking at the expanded use of left atrial ...